Susceptibility of enterococci to daptomycin is dependent upon testing methodology

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 4, 2013, Pages 497-501

  Bryant, Kendall A ^b   Roberts, Amity L ^b   Rupp, Mark E ^a   Anderson, James R ^a   Lyden, Elizabeth R ^a   Fey, Paul D ^a,b   Van Schooneveld, Trevor C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Daptomycin; Enterococcus; Susceptibility testing

Indexed keywords

DAPTOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; EPSILOMETER TEST; MICROSCAN PROMPT; MICROSCAN TURBIDITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SENSITITIRE;

DAPTOMYCIN; ENTEROCOCCUS; SUSCEPTIBILITY TESTING;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FALSE POSITIVE REACTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84880740988     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.04.019     Document Type: Article

References (31)

1. Becton DaC BD BBL™ Prompt™ Inocuation System package insert 2012, 11.
2. Canton R., Ruiz-Garbajosa P., Chaves R.L., Johnson A.P. A potential role for daptomycin in enterococcal infections: what is the evidence?. J Antimicrob Chemother 2010, 65:1126-1136.
3. Clinical Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. (CSLI Document M100-S23) 2013, CLSI, Wayne, PA.
4. Eliopoulous G.M., Kelesidis T., Humphries R., Uslan D.Z., Pegues D.A. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011, 52:228-234.
5. Erlandson K., Sun J., Iwen P., Rupp M. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Clin Infect Dis 2008, 46:30-36.
6. Fuchs P.C., Barry A.L., Brown S.D. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. J Antimicrob Chemother 2001, 48:557-561.
7. Broth microdilution MIC test. Clinical microbiology procedures handbook 2010, 5.2.1-5.2.7. ASM Press, Washington, DC. L.S. Garcia, H.D. Isenberg, L.S. Garcia, H.D. Isenberg (Eds.).
8. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
9. Johnson A.P., Mushtaq S., Warner M., Livermore D.M. Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar. J Antimicrob Chemother 2004, 53:860-862.
10. Jorgensen J.H., Crawford S.A. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J Clin Microbiol 2006, 44:2126-2129.
11. Jorgensen J.H., Crawford S.A., Kelly C.C., Patterson J.E. In vitro activity of daptomycin against vancomycin-resistant enterococci of various van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 2003, 47:3760-3763.
12. Judge T., Pogue J.M., Marchaim D., Ho K., Kamatam S., Parveen S., et al. Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin. Infect Control Hosp Epidemiol 2012, 33:1250-1254.
13. Kamboj M., Cohen N., Gilhuley K., Babady N.E., Seo S.K., Sepkowitz K.A. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol 2011, 32:391-394.
14. Keel R.A., Sutherland C.A., Aslanzadeh J., Nicolau D.P., Kuti J.L. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis 2010, 68:326-329.
15. Kelesidis T., Chow A.L., Humphries R., Uslan D.Z., Pegues D. Case-control study comparing de novo and daptomycin-exposed daptomycin-nonsusceptible enterococcus infections. Antimicrob Agents Chemother 2012, 56:2150-2152.
16. Kelesidis T., Humphries R., Uslan D.Z., Pegues D. De novo daptomycin-nonsusceptible enterococcal infections. Emerg Infect Dis 2012, 18:674-676.
17. Kelesidis T., Humphries R., Uslan D.Z., Pegues D.A. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011, 52:228-234.
18. Kruzel M.C., Lewis C.T., Welsh K.J., Lewis E.M., Dundas N.E., Mohr J.F., et al. Determination of vancomycin and daptomycin MICs by Different testing methods for methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2011, 49:2272-2273.
19. Kullar R., Davis S.L., Levine D.P., Zhao J.J., Crank C.W., Segreti J., et al. High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011, 31:527-536.
20. Ludwig F., Edwards B., Lawes T., Gould I.M. Effects of storage on vancomycin and daptomycin MIC in 'susceptible' blood isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2012, 50:3383-3387.
21. Mohr J.F., Friedrich L.V., Yankelev S., Lamp K.C. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009, 33:543-548.
22. Palavecino E.L., Burnell J.M. False daptomycin non-susceptible MIC results by MicroScan Panel PC 29 compared to Etest in Staphylococcus aureus and enterococci. J Clin Microbiol 2012.
23. Pfaller M.A., Sader H.S., Jones R.N. Evaluation of the in vitro activity of daptomycin against 19 615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007, 57:459-465.
24. Prakash V., Lewis J.S., Jorgensen J.H. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 2008, 52:4528.
25. Rathe M., Kristensen L., Ellermann-Eriksen S., Thomsen M.K., Schumacher H. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin. APMIS 2010, 118:66-73.
26. Rybak M.J., Hershberger E., Moldovan T., Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000, 44:1062-1066.
27. Sader H.S., Farrell D.J., Jones R.N. Antimicrobial activity of daptomycin tested against Gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009). J Chemother 2011, 23:200-206.
28. Sader H.S., Rhomberg P.R., Jones R.N. Nine-hospital study comparing broth microdilution and etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:3162-3165.
29. Siemens Healthcare Diagnostics I Enterococcus faecium with reduced susceptibility to daptomycin. Technical Support Bulletin 2011, 182.
30. Storm J.C., Diekema D.J., Kroeger J.S., Johnson S.J., Johannsson B. Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus. Antimicrob Resist Infect Control 2012, 1:19.
31. Turabelidze D., Kotetishvili M., Kreger A., Morris J.G., Sulakvelidze A. Improved pulsed-field gel electrophoresis for typing vancomycin-resistant enterococci. J Clin Microbiol 2000, 38:4242-4245.